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ABSTRACT
Objectives. To evaluate the efﬁcacy and safety of efalizumab in continuous or interrupted therapy of adults with
moderate-to-severe plaque psoriasis who had failed to respond to or were intolerant of other systemic therapies,
including methotrexate, ciclosporin and psoralen plus UVA phototherapy, or for whom such therapies were
contraindicated.
Methods. Patients received a conditioning dose of efalizumab 0.7 mg/kg followed by once-weekly open-label
efalizumab 1.0 mg/kg for 11 weeks. Responders (Physician Global Assessment [PGA] score of “good” or better at
Week 12) could continue efalizumab for a further 8 weeks (continuous-treatment period). Nonresponders transi-
tioned to alternative anti-psoriasis medication or stopped treatment. Responders who discontinued efalizumab could
restart treatment if symptoms worsened. PGA response was evaluated at Weeks 12 (primary endpoint) and 20, as
were the proportions of patients achieving an improvement from baseline of 50%, 75% and 90% in Psoriasis
Area and Severity Index (PASI) (PASI 50, PASI 75 and PASI 90, respectively).
Results. A total of 1,255 patients were included in the intention-to-treat population. At Week 12, 68.0% of
patients had a PGA rating of “good” or better. Of 688 patients who entered the continuous-treatment period,
79.5% had a PGA rating of “good” or better at Week 20. At Week 12, median improvement in PASI score was
68.4%. PASI 50/75/90 was achieved by 65.5%/35.9%/13.0% of patients at Week 12, and by 78.2%/52.9%/24.3%
of responders at Week 20. Of the 127 responders at Week 12 who discontinued efalizumab, 11% experienced
rebound and 56.7% relapsed within 8 weeks after stopping therapy. Efalizumab was well tolerated during the
study.
Conclusions. Efalizumab provided effective control of psoriasis in the majority of patients during the initial treat-
ment period. The high response rates were maintained in initial responders when treatment was continued beyond
12 weeks.
Key Words. Psoriasis; Efalizumab; Treatment efﬁcacy; Safety
Re-use of this article is permitted in accordance with the Terms and Conditions set out at http://www3.
interscience.wiley.com/authorresources/onlineopen.html
9
© 2009, Archives of Drug Information Arch Drug Info 2010;3:9–18Introduction
P
soriasis is a chronic inﬂammatory systemic
disease [1,2], affecting between 1–3% of the
population in Europe and the USA [3]. Plaque
psoriasis is the most common form of the disease,
accounting for more than 90% of cases [1].
Efalizumab is a recombinant humanized mono-
clonal immunoglobulin G1 antibody that binds
to the CD11a subunit of leucocyte function-
associated antigen type 1 (LFA-1). It targets
multiple stages in the immunopathogenesis of
psoriasis: initial T-cell activation, migration of
T-cells into dermal and epidermal tissues, and
T-cell reactivation [4,5]. Numerous Phase III
clinical trials have demonstrated the efﬁcacy, safety
and health-related quality of life beneﬁts of efali-
zumab in patients with moderate-to-severe
chronic plaque psoriasis [5–11].
The current study evaluated the efﬁcacy and
safety of efalizumab in the restricted, difﬁcult-to-
treat, European-label population (adult patients
with moderate-to-severe chronic plaque psoriasis
who have failed to respond to or are intolerant to
other systemic therapies), and the management of
psoriasis rebound and exacerbation during or after
efalizumab treatment. It was conducted according
to the European Summary of Product Character-
istics for efalizumab, which was current during the
time the trial was carried out.
Materials and Methods
Patients
All patients were aged 18 years with a diagnosis
of moderate-to-severe plaque psoriasis and had
failed to respond, had a contraindication to, or
were intolerant of other systemic therapies,
including ciclosporin, methotrexate and PUVA.
Patients were required to have a white blood
cell count of 4–14 ¥ 10
9/L and a platelet count of
100 ¥ 10
9/L. Systemic anti-psoriasis treatments
were discontinued before starting study treatment
withnowashoutperiod.Investigationalorbiologic-
al treatments for psoriasis (other than efalizumab)
were also stopped at least 3 months before study
treatment. Patients were not to receive any
primary vaccinations within the 14 days before
trial entry. Women of childbearing potential were
required to use adequate contraception both
during the study and for 3 months afterwards.
Patients were excluded if they met any of the fol-
lowing criteria: the sole or predominant form of
their psoriasis was guttate, erythrodermic or pus-
tular; they had a history of severe allergic reactions
to humanized monoclonal antibodies; they had
withdrawn from previous efalizumab treatment as
a result of lack of efﬁcacy or an adverse event; they
were pregnant or breastfeeding; they had a history
of opportunistic infections or ongoing uncon-
trolled infections; they were seropositive for HIV,
hepatitis B or hepatitis C; they had been hospi-
talized for cardiac disease, stroke or pulmonary
disease within the last year; they had a malignancy
within the past 5 years (other than fully resolved
basal cell or squamous cell skin cancer). Patients
with active tuberculosis (TB), a positive chest
X-ray or those who had received treatment for TB
within 1 year before entry were also excluded; a
chest X-ray within 3 months of study treatment
was required for patients considered to be at high
risk for TB. Written informed consent was
obtained from all patients enrolled in the trial.
Trial Design
This was a Phase IIIb/IV, multicentre, open-label
trial (study acronym CONTROL II [IMP25300];
ClinicalTrials.gov identiﬁer NCT00249808). The
trial was performed in accordance with the Decla-
ration of Helsinki Guidelines for Good Clinical
Practice, with approval by the independent ethics
committee/institutional review board for each
centre.
ThetrialdesignissummarizedinFigure 1.After
a single subcutaneous (s.c.) conditioning dose of
efalizumab 0.7 mg/kg, eligible patients received
open-label s.c. efalizumab at a dose of 1.0 mg/kg
once a week for a further 11 weeks (ﬁrst-treatment
period).PatientswereclassiﬁedatWeek12accord-
ing to the dynamic Physician Global Assessment
(PGA) rating as responders (“good”, “excellent” or
“cleared”) or nonresponders (“fair”, “slight”,
“unchanged” or “worse”) (Table 1).
Responders could continue to receive weekly
open-label s.c. efalizumab at 1.0 mg/kg for up to
8 weeks (continuous-treatment period). Nonre-
sponders switched to treatment with an alternative
approved anti-psoriasis medications, chosen by
their investigator, for up to 12 weeks (transition-
treatment period). Patients could choose to dis-
continue anti-psoriasis medication on completing
the ﬁrst-treatment period regardless of their
response at Week 12. These patients entered the
observation period and were monitored without
treatment for up to 8 weeks or until signs of wors-
ening psoriasis were observed indicating a possible
relapseorrebound(inresponders)ordiseaseexacer-
bation (in nonresponders).
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treatment period but experienced worsening psor-
iasis during the observation period could then
receive further treatment with weekly open-label
s.c. efalizumab at 1.0 mg/kg for 12 weeks (re-
treatment period).
Trial Assessments
PGA [12,13] and Psoriasis Area and Severity Index
(PASI) [14] (Table 1) were assessed at each visit
(Weeks 2, 4, 8 and 12) during the ﬁrst-treatment,
re-treatment and transition-treatment periods, as
well as at Week 20 (continuous-treatment period)
Figure 1 Trial design and patient
disposition. White boxes indicate
patients who entered inappropriate
treatment or assessment periods
based on their response status.
CT = continuous-treatment; FT = ﬁrst-
treatment; FU = follow-up; ITT =
intention to treat; OB = observation;
RT = re-treatment; TT = transition-
treatment.
Table 1 Assessment criteria used to evaluate patient efficacy in this study
Assessment Description
Physician Global Assessment (PGA) [12,13]
Global change vs. baseline in the clinical signs
and symptoms of all psoriatic lesions in response
to treatment (body diagrams are completed at
baseline for comparison)
Cleared 100% improvement of all clinical signs and symptoms
compared with baseline, except for residual
manifestations (e.g., mild erythema)
Excellent 75–99% improvement, except for residual manifestations
(e.g., mild erythema)
Good 50–74% improvement
Fair 25–49% improvement
Slight 1–24% improvement
Unchanged Clinical signs and symptoms unchanged from baseline
Worse Clinical signs and symptoms deteriorated from baseline
Psoriasis Area and Severity Index (PASI) [14]
Extent of cutaneous psoriasis for four anatomical
regions. Individual scores for each are summed,
with a higher score representing more severe
and extensive psoriasis
Head
Trunk
Upper limbs
Lower limbs
Severity score: 0 (none) to 4 (very severe) for each
region, for each of the following three symptoms:
erythema, induration/thickness and scaling
and proportion of region affected: 0 (none) to 6
(90–100% involvement)
Total score: 0–72
Percent improvement: Baseline PASI Week PASI
Baseline PASI
−
×
12
100
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patients who were identiﬁed as responders at
Week 12 was deﬁned as either worsening psoriasis
symptoms (125% increase in PASI score from
baseline)ortheoccurrenceofnewpustular,erythro-
dermic or more inﬂammatory psoriasis within 2
months of stopping therapy. Disease relapse was
deﬁned as a 50% reduction in the PASI improve-
ment achieved after the initial 12 weeks of treat-
ment with efalizumab.
Disease exacerbation was deﬁned in nonre-
sponders (i.e., patients with PGA ratings of “fair”,
“slight”, “unchanged” or “worse” either during or
after treatment) as worsening of disease to a more
inﬂammatory state than at baseline, and that
occurred within pre-existing plaques, at previously
uninvolved sites, or as new morphologies of the
disease.
Adverse events were assessed at every study visit
throughout the trial (Weeks 0, 2, 4, 8, 12 and 20).
Adverse events were coded using MedDRA
(version 8.1). Reported adverse events were classi-
ﬁed as pre-ﬁrst-treatment period, ﬁrst-treatment-
emergent or post-ﬁrst-treatment period events
based on their onset dates and the dates of ﬁrst and
last “ﬁrst-treatment period” treatment administra-
tion. The severity of adverse events was assessed
as mild (the patient was aware of the event or
symptom but it was easily tolerated), moderate
(the patient experienced sufﬁcient discomfort to
interfere with, or reduce, his or her usual level of
activity) or severe (the patient experienced a sig-
niﬁcant impairment of functioning and was unable
to carry out his or her usual activities). A serious
adverse event was deﬁned as an event resulting in
death or that was life-threatening, required hospi-
talization or prolongation of existing hospitaliza-
tion, resulted in persistent or signiﬁcant disability
or incapacity, was a congenital anomaly or birth
defect, or was a medically important condition (the
event did not have to be immediately life-
threatening or result in death or hospitalization,
but was clearly of major clinical signiﬁcance).
Statistical Considerations
The primary efﬁcacy endpoint was PGA response
at Week 12, with outcomes also assessed at Week
20. Patients with missing PGA assessments were
classiﬁed as nonresponders (worst-case imputa-
tion). The proportions of patients with a decrease
of 50%, 75% and 90% in PASI score from
baseline (PASI 50, PASI 75 and PASI 90 response,
respectively) were calculated at Weeks 12 and 20.
Analyses were conducted according to treat-
ment period for the intention-to-treat (ITT)
population, which included all patients who
received at least one dose of trial treatment and
who underwent at least one post-treatment efﬁ-
cacy assessment. Analyses for the safety popula-
tion, which included all patients who received at
least one dose of trial treatment, included analyses
of adverse events, safety laboratory outcomes and
vital signs. Patients on continuous treatment
who received efalizumab in accordance with the
protocol (i.e., those who had achieved a PGA
response of “good” or better at ﬁrst-treatment
Week 12) were evaluated as a subset of the whole
continuous-treatment population. Analyses for
this trial were primarily descriptive in nature and
no formal hypothesis testing was performed. Exact
95% conﬁdence intervals (CIs) for proportions
were obtained using the PROC FREQ procedure
from SAS. The PROC LIFETEST procedure
from SAS was used to generate Kaplan–Meier esti-
mates of time to rebound and disease relapse.
Results
Patients
The trial was conducted at 170 centres across 18
European countries. Between 13 December 2004
and 12 April 2006, 1,266 patients were enrolled in
the trial.
Patient disposition is shown in Figure 1. The
ITT population comprised 1,255 patients, as 11
patients were excluded because no post-baseline
efﬁcacy assessment data were recorded for them
during the ﬁrst-treatment period. A total of
688 patients continued into the efalizumab
continuous-treatment period after Week 12, of
whom 630 met the eligibility criterion for a PGA
“good” or better treatment response. The remain-
ing 58 patients were nonresponders who contin-
ued to receive efalizumab during the continuous-
treatment period despite it being a deviation from
the trial protocol. Data collected from these
patients were also analyzed as part of this study.
Sixty-eight patients transitioned to other anti-
psoriasis treatment after Week 12 (4 responders
and 64 nonresponders) and 156 patients (135
responders and 21 nonresponders) did not wish to
continue treatment and went into the observation
period, while 195 patients (57 responders and 138
nonresponders) entered a follow-up period. After
Week 12, 148 patients (27 responders and 121
nonresponders) had no follow-up. The baseline
demographics for the ITT population are summa-
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baseline PASI score > 20. Prior medications for
psoriasis included immunosuppressive agents
(ciclosporin, inﬂiximab, mycophenolate mofetil,
efalizumab, etanercept, methotrexate), retinoids
(acitretin, etretinate), phototherapy (UVB, sys-
temic and topical PUVA) and topical anti-psoriatic
medications.
Efﬁcacy with Continuous EfalizumabTreatment
Physician Global Assessment
The proportion of patients in the ITT population
(N = 1,255) with a PGA rating of “good”, “excel-
lent” or “cleared” increased throughout the ﬁrst-
treatment period, reaching 68.0% by Week 12
(N = 853; 95% CI: 65.3–70.5%; Figure 2a).
Among those who entered into the continuous-
treatment period (N = 688; ITT population),
79.5% (N = 547; 95% CI: 76.3–82.5%) had a PGA
rating of “good”, “excellent” or “cleared” at Week
20 (Figure 2b).
The ITT population for the continuous-
treatment period included the 58 nonresponder
patients mentioned previously who, in a deviation
from the trial protocol, continued to receive efali-
zumab up to Week 20. Of these, 29.3% (N = 17)
achieved a PGA rating of “good”, “excellent” or
“cleared” by Week 20.
Psoriasis Area and Severity Index
By Week 12, the median improvement from base-
line in PASI score in the ITT population was
68.4% (median PASI score at baseline of 19.55 and
6.00 at Week 12). The proportion of patients in
the ITT population with a PASI 50/PASI 75/
PASI 90 response increased throughout the ﬁrst-
treatment period to 65.5%/35.9%/13.0% at Week
12 (Figure 3a).
Table 2 Baseline patient demographics and disease
characteristics
Characteristic
ITT population
(N = 1,255)
Demography
Median age, years (range) 46.0 (18–81)
Sex, N (%)
Male 860 (68.5)
Race, N (%)
White 1,233 (98.2)
Black 6 (0.5)
Asian 10 (0.8)
Other 6 (0.5)
Median weight, kg (range) 80.0 (45.0–160.7)
Median body mass index, kg/m
2 (range)* 26.7 (16.4–64.4)
Disease characteristics
Median duration of psoriasis, years (range)
† 18.7 (0.7–66.1)
Patients with prior psoriasis therapy, N (%) 1,243 (99.0)
Patients with prior systemic therapy, N (%) 1,218 (97.1)
Patients receiving medication prior to
informed consent, N (%)
§
558 (44.1)
Ciclosporin 252 (19.9)
Acitretin 143 (11.3)
Methotrexate 106 (8.4)
Calcipotriol 47 (3.7)
Dovobet/01643201 21 (1.7)
Daivobet/01643401 18 (1.4)
Psoralens for systemic use 51 (4.0)
Clobetasol propionate 17 (1.3)
Median PASI score (range)
¶ 19.6 (0.7–67.2)
PASI score  20
‡, N (%) 611 (48.7)
*N = 1,233; †N = 1,252; ‡N = 1,266, safety population; §Medications received
by >1% of patients; ¶N = 1,254.
ITT = intention to treat; PASI = Psoriasis Area and Severity Index.
Figure 2 Proportions of patients with
a PGA rating of “good”, “excellent” or
“cleared” by visit at (a) Week 12, after
FT period (ITT population) and (b)
Week 20, after CT period. Of the CT
ITT population, 630 patients had
responded during the FT period (FT
responders), whereas the remaining
58 patients were nonresponders
who had continued to receive efali-
zumab during the CT period.
CT = continuous-treatment; FT = ﬁrst-
treatment; ITT = intention to treat;
PGA = Physician Global Assessment.
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patients in the continuous-treatment period and
the proportion of patients in the ITT population
with a PASI 50/PASI 75/PASI 90 response
increased further through the continuous-
treatment period to 78.2%/52.9%/24.3% of
responders at Week 20 (Figure 3b).
Efﬁcacy of Interrupted EfalizumabTreatment or
Transition to Alternative Anti-Psoriasis Medication
Of the 135 responders who entered the observa-
tion period and therefore had their efalizumab
therapy suspended for 8 weeks, 102 subsequently
entered the re-treatment period due to worsening
signs of psoriasis during the observation period.
The proportion with a PGA rating of “good”,
“excellent” or “cleared” increased from 20.4% at
Week 1 of the re-treatment period to 55.8% at
Week 12 (Figure 4a).
The proportion of patients who transitioned to
other anti-psoriasis treatment at Week 12 (N = 68)
and who were identiﬁed as having a PGA rating of
“good”, “excellent” or “cleared” also increased
across the transition-treatment period, from 5.9%
at Week 1 to 52.9% by Week 12 (Figure 4b).
Response rates at Week 12 of the transition-
treatment period were highest among patients
who transitioned to ciclosporin (N = 37; 64.9%
with a rating of “good”, “excellent” or “cleared”).
It should be noted, however, that most patients
received more than one treatment during this
period.
Rebound and Relapse
In total, 135 of 853 ﬁrst-treatment responders
entered the observation period. Out of the 127
evaluable patients, 56.7% (N = 72) relapsed, with a
median time to relapse of 56 days, and 11%
(N = 14) of the evaluable patients experienced
rebound during the observation period.
Disease Exacerbation
Of the 402 ﬁrst-treatment nonresponders,
37 (9.2%) experienced disease exacerbation during
the ﬁrst-treatment period. A total of 21 ﬁrst-
treatment nonresponders entered the observation
period and 64 entered the transition-treatment
period—treatment with an alternative approved
anti-psoriasis medication. Of these, 4.8% (N = 1)
and 3.1% (N = 2) experienced new or additional
exacerbation of their psoriasis during the observa-
tion and transition-treatment periods, respectively.
Overall, 12.9% (N = 52) of nonresponders experi-
enced disease exacerbation at some point during
the trial.
Safety
Exposure
The median duration of exposure to efalizumab in
the ﬁrst-treatment period was 78 days (range:
1–134 days); two patients received efalizumab for
>100 days. The median cumulative dose was
11.7 mg/kg (range: 1–18 mg/kg). The median
duration of exposure to efalizumab during the
continuous-treatment and re-treatment periods
Figure 3 Proportions of patients with
PASI 50, PASI 75 and PASI 90
responses during the FT and CT
periods (a) by visit for the ITT popula-
tion during the FT period and (b) at
Week 20 after the CT period. Of the
CT ITT population, 630 patients had
responded during the FT period (FT
responders), whereas the remaining
58 patients were nonresponders
who had continued to receive efali-
zumab during the CT period.
CT = continuous-treatment; FT = ﬁrst-
treatment; ITT = intention to treat;
PASI = Psoriasis Area and Severity
Index.
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1–373 days), respectively.
Treatment-Emergent Adverse Events
Treatment-emergent adverse events (TEAEs) are
summarized in Table 3. The most common
TEAEs in the ﬁrst-treatment period were head-
ache (25.5% of patients), pyrexia (9.6% of
patients) and inﬂuenza-like illness (8.5% of
patients), with most being of mild or moderate
severity (2,197/2,371 events, 92.7%). Severe
TEAEs occurred in 125 patients (9.9%), the most
common being headache (31 events), psoriasis (18
events) and pyrexia (10 events). The incidence of
TEAEs of all severities was lower during the
continuous-treatment period than during the ﬁrst-
treatment period (Table 3); the most common
TEAEs were psoriasis (1.7% of patients), arthral-
gia (1.0%), nasopharyngitis (0.9%) and pyrexia
(0.9%).
Twenty-two of the 68 patients (32.4%) who
received other approved psoriasis therapies
(including but not limited to retinoids, fumarates,
steroids, methotrexate, ciclosporin, PUVA and
Figure 4 Proportions of patients with a PGA rating of “good”, “excellent” or “cleared” by visit after (a) re-treatment with
efalizumab (RT period*; ITT population, N = 113) or (b) transition to an alternative anti-psoriasis agent (TT period
†; ITT
population, N = 68). *Patients had completed the FT period and responded but opted to enter the OB period rather than
continue treatment with efalizumab; efalizumab treatment was restarted when their psoriasis began to worsen during the OB
period.
†Patients had completed the FT period but had not responded and received treatment with another approved
anti-psoriasis medication. FT = ﬁrst-treatment; ITT = intention to treat; OB = observation; PGA = Physician Global Assess-
ment; RT = re-treatment; TT = transition-treatment.
Table 3 Treatment-emergent adverse-event (TEAE) summary of the safety population during efalizumab treatment
Number of patients (%)
FT period
(N = 1,266)
CT period
(N = 688)
RT period
(N = 113)
Any TEAE 785 (62.0) 122 (17.7) 46 (40.7)
Serious TEAE 60 (4.7) 10 (1.5) 3 (2.7)
TEAE leading to withdrawal* 89 (7.0) 4 (0.6) 4 (3.5)
Nervous system disorders 355 (28.0) 9 (1.3) 3 (2.7)
General disorders and administration-site conditions 318 (25.1) 10 (1.5) 5 (4.4)
Infections and infestations 212 (16.7) 35 (5.1) 19 (16.8)
Musculoskeletal and connective tissue disorders 176 (13.9) 21 (3.1) 14 (12.4)
Skin and subcutaneous tissue disorders 170 (13.4) 32 (4.7) 9 (8.0)
Gastrointestinal disorders 138 (10.9) 7 (1.0) 4 (3.5)
Malignancy 4 (0.3)
† 0 (0) 0 (0)
‡
Death 1 (0.1)
§ 0 (0) 0 (0)
*TEAEs leading to withdrawal from the study were not necessarily from the period in which they emerged. †Three were considered unrelated or unlikely to be related
and one possibly related to study treatment. ‡One malignancy, cutaneous squamous cell carcinoma reported during the follow-up period after RT 6 weeks after
the last efalizumab dose, was considered possibly related to study treatment. §Cardiopulmonary failure (deemed unlikely to be related to trial treatment).
CT = continuous-treatment; FT = ﬁrst-treatment; RT = re-treatment.
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reported TEAEs. Among those events reported
by 5% of patients, musculoskeletal disorders
(11.8%) and skin disorders (8.8%) were the most
common, followed by fatigue, feeling cold,
inﬂuenza-like illness and pyrexia (each 5.9%).
During the re-treatment period, a total of 77
TEAEs were reported in 40.7% of patients. The
most common TEAEs reported during the
re-treatment period were nasopharyngitis (8.8%),
arthralgia (3.5%) and back pain (3.5%).
Serious TEAEs
Fewer than 5% of patients experienced serious
TEAEs during the ﬁrst-treatment period, with
lower incidences reported during the continuous-
treatment and re-treatment periods (Table 3). The
most common serious events were psoriasis
(1.1%), psoriatic arthropathy (0.5%) and pyrexia
(0.3%). Serious TEAEs during the ﬁrst-treatment
period are summarized in Table 4.
One patient, a 71-year-old man, died during the
trial. This patient had received a single dose of
efalizumab before being withdrawn because of an
upper respiratory infection and fever. A month
later he experienced fatal cardiopulmonary failure.
This event was considered by the investigator as
unlikely to be related to trial medication.
Other Signiﬁcant TEAEs
During the ﬁrst-treatment period 89 subjects
(7.0%) had 134 adverse events that led to treat-
ment discontinuation. Of these events, the most
frequent were due to skin and s.c. tissue disorders,
general disorders and administration-site condi-
tions, and musculoskeletal and connective tissue
disorders (Table 5).
Four malignancies were reported during the
ﬁrst-treatment period: two men (aged 57 and 44
years) with basal cell carcinoma, a 49-year-old
woman and a 43-year-old man with squamous cell
carcinoma. Only the last case was considered to
possiblyberelatedtotrialtreatment.Thepatientin
question had a history of squamous and basal cell
carcinoma. An additional cutaneous squamous cell
carcinoma was reported during follow-up. This
occurred 6 weeks after the last efalizumab dose
given during the re-treatment period and was con-
sidered to possibly be related to study treatment.
The most frequently reported infection-related
TEAEs during the ﬁrst-treatment period were
nasopharyngitis (3.2%), inﬂuenza (2.2%) and
herpes simplex (1.9%). Infections and infestations
were the most common TEAEs in the continuous-
treatment and re-treatment periods (Table 3) and
accounted for 10 (0.8%) of the serious TEAEs
reported during the ﬁrst-treatment period.
With the exception of two cases of severe inﬂu-
enza in two patients (0.1%) and two cases of severe
bronchitis in two patients (0.1%), no other severe
infections occurred in more than one patient.
There were no reports of TB, opportunistic infec-
tion, demyelinating disease or serious thrombo-
cytopenia in any patients during this trial.
Table 4 Serious treatment-emergent adverse events
(TEAEs) in the safety population during the ﬁrst-treatment
period with efalizumab
Number of patients
(%) (N = 1,266)
Any serious TEAEs 60 (4.7)
Skin and subcutaneous tissue disorders 21 (1.7)
Musculoskeletal and connective tissue
disorders
10 (0.8)
Infections and infestations 10 (0.8)
General disorders and administration-site
conditions
7 (0.6)
Cardiac disorders 6 (0.5)
Gastrointestinal disorders 5 (0.4)
Nervous system disorders 5 (0.4)
Immune system disorders 2 (0.2)
Injury, poisoning and procedural
complications
2 (0.2)
Malignancy 2 (0.2)
Ear and labyrinth disorders 1 (0.1)
Eye disorders 1 (0.1)
Hepatobiliary disorders 1 (0.1)
Psychiatric disorders 1 (0.1)
Respiratory, thoracic and mediastinal
disorders
1 (0.1)
Table 5 Treatment-emergent adverse events (TEAEs)
leading to withdrawal in the safety population during the
ﬁrst-treatment period with efalizumab
Number of patients
(%) (N = 1,266)
Any TEAE leading to withdrawal 89 (7.0)
Skin and subcutaneous tissue disorders 30 (2.4)
General disorders and administration-site
conditions
22 (1.7)
Musculoskeletal and connective tissue
disorders
17 (1.3)
Infections and infestations 12 (0.9)
Gastrointestinal disorders 9 (0.7)
Nervous system disorders 8 (0.6)
Investigations 4 (0.3)
Cardiac disorders 4 (0.3)
Blood and lymphatic system disorders 3 (0.2)
Immune system disorders 3 (0.2)
Vascular disorders 3 (0.2)
Psychiatric disorders 2 (0.2)
Ear and labyrinth disorders 1 (0.1)
Eye disorders 1 (0.1)
Metabolism and nutrition disorders 1 (0.1)
Malignancy 1 (0.1)
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This prospective, post-approval clinical trial
assessed the efﬁcacy and safety of efalizumab
therapy in patients across Europe with moderate-
to-severechronicplaquepsoriasiswhohadfailedto
respond to, had contraindications for, or were
intolerant of other systemic therapies. The main
strengthsofthisstudywerethelargepatientcohort
and the unique study design, which enabled a more
accurate reﬂection of routine clinical practice by
allowing patients receiving other anti-psoriasis
drugs,thosenotreceivinganytreatment,andthose
restarting treatment to continue follow-up.
Results obtained from the initial continuous-
treatment section of the trial show that over two-
thirds of patients had responded by Week 12 of
efalizumab treatment and this high response rate
was maintained in responders who continued
treatment for up to 20 weeks. These ﬁndings are
consistent with data obtained from previous
pivotal clinical trials, the open-label LATAM trial
and longer-term studies [6,8–11,15].
Following this initial 12-week treatment period,
the ﬁndings from this study indicate that efali-
zumab treatment can be discontinued, if alterna-
tive therapy is initiated in its place. Of the
responders who stopped efalizumab treatment at
the end of the initial 12-week period and did not
transition to an alterative therapy, 11% experi-
enced rebound. Responding patients who had dis-
continued and then restarted efalizumab treatment
were found to achieve a similar (but slightly
reduced) efﬁcacy and tolerability as attained
during the initial treatment period.
This trial also explored treatment options for
patients who do not initially respond to efalizumab
therapy. More than half of the nonresponders who
entered the transition-treatment period subse-
quently achieved a response after changing to
another anti-psoriatic therapy.
The major limitation of this study was the open-
label, noncomparative trial design. Indeed, the
range of anti-psoriatic therapies permitted across
the transition-treatment period, while an accurate
reﬂection of real-life clinical experience, compli-
cates the analysis of treatment effectiveness during
this time. It is also difﬁcult to interpret the data
obtained during the observation period, since few
nonresponders entered this section of the study.
The incidence of psoriasis exacerbation in non-
responders was carefully monitored, but found to
be lower after the initial 12-week treatment
period, indicating that the discontinuation of
efalizumab in these patients was not associated
with psoriasis-related adverse events. Due to the
immunomodulatory mechanism of action of
efalizumab, the incidences of infections and
malignancies in treated patients were also followed
closely. During this trial the safety of efalizumab
was found to be acceptable and consistent with
previous results. No new safety issues were iden-
tiﬁed. The incidence of TEAEs was lower in the
continuous-treatment period than in the initial-
treatment period, with inﬂuenza-like symptoms
being the most frequent TEAEs in the ﬁrst-
treatment period, as observed in previous studies
[5–10]. Unlike trials examining tumour necrosis
factor blocking agents, no increase in the risk of
TB with treatment with efalizumab was observed
[16]. Four malignancies were reported during the
ﬁrst-treatment period but the number of cases in
this study was not sufﬁcient to draw any ﬁrm con-
clusions regarding the risk of malignancy with this
drug.
No TEAEs related to opportunistic infections
were observed during this trial. However, oppor-
tunistic infections have been reported in the post-
marketing surveillance in patients with psoriasis
receiving efalizumab. In particular, cases of JC
virus infection resulting in progressive multifocal
leucoencephalopathy have been reported in
patients receiving efalizumab continuously for
more than 3 years. After evaluating all available
safety data, the European Medicines Agency con-
cluded that the beneﬁts of efalizumab treatment
no longer outweighed the risks associated with the
drug and recommended suspension of marketing
authorization on 19 February 2009.
This study addressed important questions relat-
ing to the appropriate management of both
responding and nonresponding psoriasis patients
in real-life clinical situations, beyond the initial
12-week treatment period. Efalizumab was found
to provide effective control of psoriasis in two-
thirds of patients within 3 months of treatment. Of
127 evaluable patients who entered the observa-
tion period, more than half relapsed and 11%
(N = 14) experienced rebound during the observa-
tion period. However, the greatest therapeutic
beneﬁt was obtained by initially responding
patients who were given continuous efalizumab-
treatment for the full 5-month trial period.
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